Department of Biotechnology
Molecular Biotechnology
 Home | Organization | Staff  | Research | Core facilities | Courses | Directions | Links | Intranet


Stefan Ståhl


KTH Biotechnology
AlbaNova University Center
Royal Institute of Technology
106 91 Stockholm, Sweden

Direct phone: +468 5537 8329
Fax: +46 8 5537 8482


Short Biography

Stefan Ståhl is Professor in Molecular Biotechnology, and was appointed as Dean for the School of Biotechnology in January 2005.
The major present focus for the group, Biotherapy and Bacterial Display is in evaluating affibody-mediated biotherapy approaches. A novel class of affinity proteins, denoted affibody ligands, has been developed at our department. Their potential in various therapeutic settings are investigated, including tumor targeting for medical imaging and radiotherapy applications. In addition, a staphylococcal surface display system has been developed by the group. The system has become a platform for protein engineering application, using fluorescence activated cell sorting (FACS) as a powerful analytical tool. The system is presently evaluated for selection of affinity proteins, i.e. affibody molecules and domain antibodies, using surface-displayed libraries, as well as epitope mapping of polyclonal and monoclonal antibodies.
Entrepreneural activities: Stefan is cofounder of the biotech companies Creative Peptides AB (1996), Affibody AB (1998) and Visual Bioinformatics AB (1999). Between April 2000 and Dec 2002 he acted as Chief Scientific Officer at Affibody AB, while the company grew from four to 65 employees, still retaining PhD students and research activity at KTH.
Scientific output: Stefan is the inventor of a number of patents, and has published more than 160  scientific papers in international peer-reviewed journals, and has supervised 19 PhD students to their dissertation (see below).
Dissertations from the group:
1994 Stabilization of recombinant proteins produced in E. coli. (co-supervised w. M. Uhlén) Maria Murby Phadia AB
1998 Recombinant subunit vaccines: protein immunogens, live bacteria and nucleic acids Sissela Lijeqvist Karolinska Institutet
1998 Design, selection and production of recombinant proteins for the prevention of infectious diseases Marianne Hansson CEO, Atlas Antibodies AB
1998 Strategies for vaccine development applied to Plasmodium falciparum asexual blood-stage antigens Pf332 and Pf155/RESA Diana Haddad Johns Hopkins, Baltimore, USA
1999 Genetic design for facilitated production of human peptide hormones in Escherichia coli Per Jonasson Affibody AB
1999 Staphylococcal surface display and its applications in bioscience Patrik Samuelson KTH (group leader)
1999 Display of affinity proteins on bacteria and bacteriophage" (Co-supervised w. Nygren) Elin Gunneriusson Affibody AB
1999 Functional genomics and proteomics: analysis of cDNA and encoded proteins Magnus Larsson CEO, Fiber-staden AB
2000 Production and delivery of recombinant subunit vaccines Christin Andersson AstraZeneca
2002 Functional Proteomics: generation and analysis of cDNA-encoded proteins Susanne Gräslund SGC, Toronto
2002 Engineering of staphylococcal surfaces for biotechnological applications Henrik Wernérus Atlas Antibodies
2005 Rational and combinatorial protein engineering for vaccine delivery and drug targeting Maria Wikman Peviva AB
2008 Staphylococcal surface display for protein engineering and characterization John Löfblom KTH (PostDoc)
2008 Affibody molecules for proteomic and therapeutic applications Caroline Grönwall NYU, USA
2008 Affibody molecules targeting the epidermal growth factor receptor for tumor imaging applications Mikaela Friedman Uppsala Univ.
2009 Development of molecular recognition by rational and combinatorial engineering Andreas Jonsson KTH
2009 Staphylococcal surface display in directed evolution Nina Kronqvist Karolinska Institutet
2011 Intracellular systems for characterization and engineering of proteases and their substrates (co-supervised with P. Samuelson) George Kostallas Karolinska Institutet
2011 Design and evaluation of radiolabeled affibody tracers for imaging of HER2-expressing tumors. Helena Wållberg KTH
Last updated: 2012-06-13